QualityStocksNewsBreaks Archives - Page 115 of 1580

WednesdayDec 03, 2025 3:30 pm

QualityStocksNewsBreaks – Gloo Holdings, Inc. (NASDAQ: GLOO) Prices $72.8 Million IPO

Gloo (NASDAQ: GLOO) , a technology platform serving the faith and flourishing ecosystem, priced its initial public offering of 9,100,000 shares of Class A common stock at $8 per share and granted underwriters a 30-day option to purchase up to 1,365,000 additional shares. Trading is expected to begin on the Nasdaq Global Select Market under the symbol GLOO, with the offering slated to close Nov. 20, 2025, subject to customary conditions. Roth Capital Partners is serving as sole book-running manager, with The Benchmark Company, Craig-Hallum Capital Group, Lake Street Capital Markets, Loop Capital Markets, and Texas Capital Securities acting as…

WednesdayDec 03, 2025 2:33 pm

QualityStocksNewsBreaks – Decent Holding Inc. (NASDAQ: DXST) Closes $8 Million Registered Offering of Class A Shares and Warrants

Decent Holding (NASDAQ: DXST), an established wastewater treatment services provider in China, closed its $8 million registered offering consisting of 13,333,333 Class A ordinary shares at $0.60 per share and warrants to purchase 26,666,666 additional shares at 110 percent of the offering price with a 120-day term. Gross proceeds totaled $8 million before expenses, and the company plans to use the net proceeds to support business expansion, R&D, river-water quality management initiatives, wastewater treatment technology upgrades, and talent recruitment. The offering was conducted on a reasonable best-effort basis, with D. Boral Capital LLC serving as placement agent. To view the…

WednesdayDec 03, 2025 12:26 pm

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% JV Reports IV Sapu003 Cuts GI Exposure to Everolimus by Up to 67-Fold

Oncotelic Therapeutics (OTCQB: OTLC), 45% owner of the Sapu Nano joint venture, announced new pharmacokinetic and tissue-distribution data showing that Sapu003, its intravenous Deciparticle (TM) formulation of everolimus, dramatically reduces gastrointestinal drug accumulation compared with oral everolimus. Oral dosing drives extreme gut exposure—up to 2,448× plasma levels in the stomach—while IV Sapu003 limits GI tissue levels to just 36–48× plasma, representing reductions of up to 67-fold. The company stated that this shift may improve tolerability, maintain the drug’s intrinsic metabolic profile, and provide more consistent systemic exposure. To view the full press release, visit https://ibn.fm/TWsDZ About Oncotelic Therapeutics Inc. Oncotelic Therapeutics…

WednesdayDec 03, 2025 11:45 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 along with highlights from a recent webinar. The study in 63 heavily pre-treated patients with advanced solid tumors met all primary endpoints for safety and tolerability and established a clear recommended Phase 2 dose. Encouraging signals of durable disease control were observed, particularly in tumors with DNA damage repair pathway deficiencies. Building on these results, Lantern is advancing multiple biomarker-guided Phase 1b/2 trials across triple-negative breast cancer,…

WednesdayDec 03, 2025 11:44 am

QualityStocksNewsBreaks – Micropolis AI Robotics (NYSE: MCRP) Signs LOI With QSS Robotics to Expand Deployment in Saudi Arabia

Micropolis AI Robotics (NYSE American: MCRP), a UAE-based developer of autonomous mobile robots and AI-driven security solutions, said it signed a non-binding Letter of Intent with QSS Robotics to establish a strategic collaboration for the distribution, localization, and deployment of Micropolis technologies across Saudi Arabia. The LOI outlines plans for commercial representation, joint engagement with government and private-sector customers, and integration and after-sales support under Micropolis supervision, building on agreements between the companies dating to 2022. Micropolis will provide its full suite of technologies, including M01 and M02 autonomous mobility platforms, Mission Planner and HD Mapping systems, Tele-Operator tools, and…

WednesdayDec 03, 2025 11:29 am

QualityStocksNewsBreaks – A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) Reaches Agreement With Major Central American Grocer to Deploy Smart Cart Platform

A2Z Cust2Mate Solutions (NASDAQ: AZ), a global smart retail technology company, said it entered an agreement with a premium grocery retailer operating more than 50 stores in Central America to deploy the A2Z Cust2mate smart cart platform. Initial rollout is planned for early 2026 in two flagship locations, with the shared goal of expanding to a full chain-wide deployment following successful implementation. The Company said the agreement marks a significant milestone for large-scale smart cart adoption in Central America, supported by its regional channel partner Trixo, and will help redefine the in-store experience, enhance retail media opportunities, and generate new…

WednesdayDec 03, 2025 10:15 am

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial Highlighting HyBryte(TM) and Rare Disease Policy

Soligenix (NASDAQ: SNGX) was featured in a BioMedWire editorial titled “Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,” which examines the growing burden of rare diseases affecting more than 30 million Americans and the urgent need for new therapies. The article spotlights Soligenix’s late-stage development of HyBryte(TM) (synthetic hypericin) for cutaneous T-cell lymphoma, now in its final confirmatory study before worldwide marketing submissions, and places the Company’s efforts at the intersection of advancing treatment options and emerging national health policy initiatives. To view the full press release, visit https://ibn.fm/OFZZt About Soligenix Soligenix is a…

WednesdayDec 03, 2025 9:54 am

QualityStocksNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Forms U.S. Government Business Unit Led by Jack Sears Jr.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”) formed a new business unit dedicated to driving the adoption of its quantum computing products and services within the U.S. government. Led by seasoned government and public sector business executive Jack Sears Jr., the newly established unit will support D-Wave’s enterprise-wide U.S. government-related initiative. Sears will join D-Wave’s executive team and serve as the business unit’s vice president of U.S. government solutions. In his role, Sears will oversee government-related go-to-market efforts and application development as well as the unique product development and customer support necessary for secure systems that meet federal requirements. He brings…

WednesdayDec 03, 2025 9:25 am

QualityStocksNewsBreaks – Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) Settles $404K Debt Through Shares-for-Debt Transaction

This article has been disseminated on behalf of Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) and may include paid advertising. Search Minerals (TSX.V: SMY) (OTC: SHCMF) said it entered a transaction with LeadFX Inc. to settle $404,053.73 of outstanding debt through the issuance of 808,107 common shares at a deemed price of $0.50 per share. The Company said completing the Shares-for-Debt transaction, rather than proceeding with a previously planned unsecured convertible loan, will preserve cash and strengthen its balance sheet. The shares will carry a four-month-and-one-day statutory hold period. Because LeadFX is a related party, the transaction falls under MI…

WednesdayDec 03, 2025 9:15 am

QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it amended its Investigational New Drug filing for NRX-101 to include use of the drug in combination with Transcranial Magnetic Stimulation for depression, including suicidal depression. The update follows evidence suggesting NRX-101 may significantly enhance TMS outcomes, with published studies showing more than two-fold improvements in symptom reduction and clinical response rates exceeding 80%. The Company noted NRX-101’s D-cycloserine component appears to augment neuroplasticity associated with TMS, while its low-dose lurasidone is intended to mitigate D-cycloserine’s known risk of low-grade hallucinations. NRx said it aims to validate the findings in a…

Site Search

Company Search

Category: QualityStocksNewsBreaks